After a deadly clinical trial, will immune therapies for cancer be a bust?
By Damian Garde,
STAT
| 07. 08. 2016
Immune therapies have been hailed as the future of cancer treatments, with new drugs racking up excellent clinical results by turning the body’s natural defenses on tumors.
But Thursday’s news that three patients died in a trial of one such treatment has surprised oncologists and biotech investors, casting doubts on what looked like a blockbuster new approach to fighting cancer.
Here’s a rundown on the fatal trial and what it means for the rest of the field.
Continue reading on STAT
Image via Flickr/NIH Image Gallery
Related Articles
By Megan Molteni and Anil Oza, STAT | 10.07.2025
For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...
By Shoumita Dasgupta, STAT | 10.03.2025
President Trump and health secretary Robert F. Kennedy Jr. have characterized the rise in autism diagnoses in recent years as an epidemic requiring emergency intervention.
This approach is factually wrong: The broadening definition of autism and the improvement in diagnosis...
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Émile P. Torres, Truthdig | 10.17.2025
The Internet philosopher Eliezer Yudkowsky has been predicting the end of the world for decades. In 1996, he confidently declared that the singularity — the moment at which computers become more “intelligent” than humanity — would happen in 2021, though...
